NEW YORK (GenomeWeb) – AstraZeneca will use Myriad Genetics' myChoice HRD Plus diagnostic panel in a clinical trial to identify advanced ovarian cancer patients who respond best to maintenance treatment with a combination of its PARP inhibitor Lynparza (olaparib) and Avastin (bevacizumab).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.